Cognition Therapeutics, Inc. (CGTX) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 6 Buy, 1 Hold.
Analysts estimate Earnings Per Share (EPS) of $-0.82 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.86 vs est $-0.82 (missed -4.7%). 2025: actual $-0.32 vs est $-0.39 (beat +17.9%). Analyst accuracy: 87%.
CGTX Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to Cognition Therapeutics, Inc. in the past 3 months
EPS Estimates — CGTX
87%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.86
vs Est –$0.82
▼ 4.5% off
2025
Actual –$0.32
vs Est –$0.39
▲ 21.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CGTX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
